Zhao Cheng, Hao Xing, Xue Chao, Zhao Yichen, Han Jie, Jia Yixin, Hou Xiaotong, Wang Jiangang
Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Department of Intensive Care, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Front Cardiovasc Med. 2022 Jul 15;9:938442. doi: 10.3389/fcvm.2022.938442. eCollection 2022.
Acute right ventricular failure remains a common challenging clinical syndrome in heart transplant (HTx) recipients. While extracorporeal membrane oxygenation (ECMO) is a proven strategy for the treatment of this condition, the outcomes after weaning and during follow up remain understudied. We aimed to evaluate the right-sided heart function in ECMO survivors following HTx.
Between September 2005 and December 2019, 205 patients with end-stage heart failure who underwent standard orthotopic HTx were enrolled. In total, 68 (33.2%) patients were included in the ECMO group and 137 (66.8%) patients were included in the non-ECMO group.
Of the 68 patients in the ECMO group, 42 (61.8%) were successfully weaned from ECMO. After a median follow-up period of 53 months, there were 25 (59.5%) and 27 (23.7%) deaths in the ECMO and non-ECMO groups ( = 0.023), respectively. Systolic pulmonary artery pressure (SPAP) before discharge ( = 0.003) was the unique predictor of all-cause mortality during follow up. Meanwhile, patients in the ECMO group with more than moderate SPAP increase before discharge had higher mortality than patients in the non-ECMO group without such increase ( = 0.005).
Recipient right-sided heart characteristics were strong predictors of ECMO need after HTx. ECMO patients had high mortality in the perioperative and follow-up periods, and the changes in right ventricular function in ECMO patients may be associated with pulmonary vessel injury before and after HTx.
急性右心室衰竭在心脏移植(HTx)受者中仍然是一种常见且具有挑战性的临床综合征。虽然体外膜肺氧合(ECMO)是治疗这种疾病的一种已被证实的策略,但脱机后及随访期间的结局仍未得到充分研究。我们旨在评估HTx后ECMO存活者的右心功能。
2005年9月至2019年12月,纳入205例接受标准原位HTx的终末期心力衰竭患者。总共68例(33.2%)患者被纳入ECMO组,137例(66.8%)患者被纳入非ECMO组。
ECMO组的68例患者中,42例(61.8%)成功脱离ECMO。中位随访期53个月后,ECMO组和非ECMO组分别有25例(59.5%)和27例(23.7%)死亡(P = 0.023)。出院前的收缩期肺动脉压(SPAP)(P = 0.003)是随访期间全因死亡率的唯一预测因素。同时,出院前SPAP升高超过中度的ECMO组患者的死亡率高于无此类升高的非ECMO组患者(P = 0.005)。
受者的右心特征是HTx后ECMO需求的强预测因素。ECMO患者在围手术期和随访期死亡率较高,ECMO患者右心室功能的变化可能与HTx前后的肺血管损伤有关。